Vertex Pharmaceuticals Incorporated (VRTX)

Biotechnology company, one pharmaceutical pattern, 81% U.S. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 13, 2026. Ranked 69 of the 104 Healthcare companies read so far, by the share within reach now.

Vertex’s approximately 6,400 employees, 5,200 in the U.S., research, develop, make and sell medicines in one pharmaceutical segment, read as one pattern.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

6,400 employees as of December 31, 2025 (stated). Approximately 5,200 of 6,400 employees are based in the U.S. and 1,200 outside it, by the filing.

The filing: “As of December 31, 2025, we had approximately 6,400 employees. Of these employees, approximately 5,200 were based in the U.S. and approximately 1,200 were based outside the U.S.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 6,400 employees, 5,200 in the U.S.; no U.S. employees under a collective bargaining agreement, a small number outside the U.S. covered by local agreements.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

6 sentences in the filing name AI. The filing names AI six times, as risks: adversarial AI in cyber threats, and the ethical and legal challenges of using AI for productivity.

• “Recent developments in the threat landscape include the use of adversarial artificial intelligence techniques and machine learning, as well as an increased number of cyber extortion attacks with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques.”
• “In addition, we face certain risks as we seek to leverage artificial intelligence to optimize productivity and efficiency in various aspects of the organization.”
• “Ethical and legal challenges may arise, including biases or discrimination in generated outcomes, non-compliance with data protection regulations and laws specifically governing the use of artificial intelligence systems and tools, and lack of transparency.”
• “Furthermore, the deployment of artificial intelligence systems could expose us to increased cybersecurity threats, such as data breaches and unauthorized access.”
• “We also face competitive risks if we do not implement artificial intelligence or other machine learning technologies in a timely fashion. 35 Our operations may be disrupted by the occurrence of a natural disaster, catastrophic event, or by other serious accidents occurring at our facilities.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20232median 1
• Fiscal 20242median 4
• Fiscal 20256median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by function; one pharmaceutical pattern by description.

Source: the company's annual report on EDGAR, accession 0000875320-26-000056, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.